PODD vs. ABMD, PEN, IRTC, EW, DXCM, IDXX, RMD, STE, HOLX, and BAX
Should you be buying Insulet stock or one of its competitors? The main competitors of Insulet include Abiomed (ABMD), Penumbra (PEN), iRhythm Technologies (IRTC), Edwards Lifesciences (EW), DexCom (DXCM), IDEXX Laboratories (IDXX), ResMed (RMD), STERIS (STE), Hologic (HOLX), and Baxter International (BAX). These companies are all part of the "medical" sector.
Insulet (NASDAQ:PODD) and Abiomed (NASDAQ:ABMD) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, institutional ownership, valuation, dividends, community ranking, earnings, profitability and media sentiment.
Insulet has a beta of 1.14, suggesting that its share price is 14% more volatile than the S&P 500. Comparatively, Abiomed has a beta of 1.4, suggesting that its share price is 40% more volatile than the S&P 500.
94.5% of Abiomed shares are held by institutional investors. 0.5% of Insulet shares are held by insiders. Comparatively, 2.5% of Abiomed shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Insulet presently has a consensus price target of $239.18, indicating a potential upside of 24.95%. Given Insulet's higher possible upside, equities research analysts clearly believe Insulet is more favorable than Abiomed.
Abiomed has a net margin of 24.84% compared to Insulet's net margin of 13.14%. Insulet's return on equity of 34.06% beat Abiomed's return on equity.
In the previous week, Insulet had 6 more articles in the media than Abiomed. MarketBeat recorded 6 mentions for Insulet and 0 mentions for Abiomed. Insulet's average media sentiment score of 1.43 beat Abiomed's score of 0.44 indicating that Insulet is being referred to more favorably in the media.
Insulet has higher revenue and earnings than Abiomed. Insulet is trading at a lower price-to-earnings ratio than Abiomed, indicating that it is currently the more affordable of the two stocks.
Insulet received 178 more outperform votes than Abiomed when rated by MarketBeat users. Likewise, 66.08% of users gave Insulet an outperform vote while only 61.92% of users gave Abiomed an outperform vote.
Summary
Insulet beats Abiomed on 9 of the 17 factors compared between the two stocks.
Get Insulet News Delivered to You Automatically
Sign up to receive the latest news and ratings for PODD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PODD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
